Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Tecfidera(®): an approach for repurposing.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Good Early Results for HERV Suppressor in MS
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Cyclophosphamide
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
HL-A antigens and multiple sclerosis.
ALSUntangled No. 8: Low dose naltrexone for ALS.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.

Pages